News & Publications

Dr Kleen brings extensive experience in immunology and immune monitoring to help further advance the company’s lead, novel immuno-oncology product, IMM-101 Uxbridge, UK, 23 May 2019 – Immodulon, the immuno-oncology company, today announces the appointment of Thomas O....

Immodulon, the immuno-oncology company, is pleased to announce that Ruslan Croitoru (MD MSc (Oxon) MFPM) will be joining the Immodulon Core Management Team as the Chief Medical Officer. Ruslan is a cardiologist. He gained his medical degree in Moldova, where he...

Immodulon, the immuno-oncology company, is pleased to announce that Maikel Dijkstal will be joining the Immodulon Core Management Team as CMC Programme Manager with immediate effect. Based in The Netherlands, Maikel has spent much of his working career in...

Immodulon, the immuno-oncology company, announces that their IMM-101-015 Phase II clinical trial has commenced. The open-label clinical study will assess the safety and efficacy of the combination of IMM-101 with Nivolumab, an immune checkpoint inhibitor, in 26...

Immodulon, the immuno-oncology company, is pleased to announce that Dr Kevin Bilyard, who served as CEO of Immodulon from 2008 to 2016 and more recently been an advisor to the company's Board of Directors, has accepted a position on the Immodulon Board. His career...

Immodulon, the immuno-oncology company, today announces the appointment of Dr Jaap Kampinga, current Chief Scientific Officer (CSO), as Chief Executive Officer (CEO) effective from 1st July 2018. Dr Kampinga is a medical doctor and immunologist and has considerable...